Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
January 05 2021 - 4:05PM
Business Wire
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty
pharmaceutical company leveraging its novel technology platforms to
develop and commercialize ready-to-use injectable and infusible
drug formulations, today announced that Paul R. Edick, Chairman and
Chief Executive Officer of Xeris Pharmaceuticals, will present an
overview of the Company at the H.C. Wainwright BioConnect 2021
virtual conference being held January 11-14, 2021.
A webcast of the on-demand presentation will be available
beginning January 11, 2021 at 6:00 a.m. E.T. through the investors
section on the Company's website at www.xerispharma.com.
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company
delivering innovative solutions to simplify the experience of
administering important therapies that people rely on every day
around the world.
With a novel technology platform that enables ready-to-use,
room-temperature stable formulations of injectable and infusible
therapies, the company is advancing a portfolio of solutions in
various therapeutic categories, including its first commercial
product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation
technologies have the potential to offer distinct advantages over
conventional product formulations, including eliminating the need
for reconstitution, enabling long-term, room-temperature stability,
significantly reducing injection volume, and eliminating the
requirement for intravenous (IV) infusion. With Xeris’ technology,
new product formulations are designed to be easier to use by
patients, caregivers, and health practitioners and help reduce
costs for payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow us on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005826/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024